Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our preclinical work indicates that anlotinib acts as a novel inhibitor of VEGFR2 and MET that blocks tumorigenesis in osteosarcoma, which could be translated into future clinical trials.
|
30719715 |
2019 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression levels of miR-206, PAX3, and MET mRNA were explored in paired OS and adjacent tissue specimens.
|
30666838 |
2019 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In rare tumour types we observed, amongst others, a predicted overexpression rate of 55% of samples for CD22 and 55% for ENPP3 in adrenocortical carcinomas, 81% for CD74 and 81% for FGFR3 in osteosarcomas, and 95% for c-MET in uveal melanomas.
|
29045509 |
2017 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our data assessed specific miRNA profiling deregulation in OS clinical samples and suggest that the expression of miR-1 and miR-133b may control cell proliferation and cell cycle through MET protein expression modulation.
|
23229283 |
2013 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Met interacts with EGFR and Ron in canine osteosarcoma.
|
22235915 |
2013 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors.
|
22367914 |
2012 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The Met receptor tyrosine kinase (RTK) is aberrantly expressed in human osteosarcoma and is an attractive molecular target for cancer therapy.
|
19402129 |
2009 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of MET, obtained by lentiviral vector-mediated gene transfer, resulted in the conversion of primary human osteoblasts into osteosarcoma cells, displaying the transformed phenotype in vitro and the distinguishing features of human osteosarcomas in vivo.
|
16651428 |
2006 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells.
|
14524531 |
2003 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
We analyzed the effect of the MET receptor activation in five human osteosarcoma cell lines evaluating the levels of HGF-dependent activation of MAPK and PKB/AKT as biochemical readouts of mitogenic and invasive responses, respectively.
|
12709413 |
2003 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We previously demonstrated that the MET oncogene was aberrantly expressed in a high percentage of human osteosarcomas.
|
10815826 |
2000 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We have previously found that bone sarcomas express high levels of Met/HGF receptor while in some cases the ligand HGF is co-expressed with the receptor, activating an autocrine loop.
|
10867643 |
2000 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The finding of Met/HGF receptor overexpression in all of the osteosarcomas suggests a role for the met proto-oncogene in the pathogenesis of this tumor.
|
8863670 |
1996 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that activation of the Met/HGF receptor by a paracrine or an autocrine mechanism might play a role in the particularly aggressive behaviour of osteosarcomas.
|
7862451 |
1995 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The TPR-MET oncogenic rearrangement was originally observed in an in vitro transformed human osteosarcoma cell line.
|
2052572 |
1991 |